Re: AACR 2018

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: AACR 2018

in response to

Re: AACR 2018

BearDownAZ

posted on Apr 13, 2018 09:23AM

AACR 2018 kicks off tomorrow in Chicago. April 14-18. Quite a number of BET inhibitor presentations there, including some in the prostate cancer area. Last I heard, Zenith is not presenting. It will still be wise to follow these developments. #AACR2018. If you see or hear anything noteworthy related to BET inhibitors and mCRPC, please share on this board.